For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed.

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

Finerenone reduced the composite of total first and recurrent heart failure (HF ... in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical ...

Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024SOUTH SAN ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Quotient Sciences, Vasa Therapeutics dose first human subjects with VS-041, a novel therapy for heart failure with preserved ejection fraction: Nottingham, UK Monday, September 16 ...

The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New Engla ...

Finerenone reduced heart failure (HF) events and cardiovascular death in patients with HF and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), according to late-breaking research ...